Terrapin, Taiho deal

The companies entered into a definitive agreement to advance the development of Terrapin's TER286 broad spectrum cancer compound. Taiho will provide R&D funding and Terrapin will be responsible for preclinical testing and preparation for an IND in the U.S. Upon successful completion of studies leading to an IND, Taiho could obtain commercialization rights in Japan and possibly other Asian countries. Terrapin would retain all other rights worldwide. ...